(Q42689992)

4 November 2017

title

The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine (English)

1 reference

4 November 2017

2

Michael F Green

1 reference

4 November 2017

Robert S Kern

1

1 reference

4 November 2017

Barbara A Cornblatt

3

1 reference

4 November 2017

J Randall Owen

4

1 reference

4 November 2017

Robert D McQuade

5

1 reference

4 November 2017

William H Carson

6

1 reference

4 November 2017

Mirza Ali

7

1 reference

4 November 2017

Ron Marcus

8

1 reference

4 November 2017

publication date

30 June 2006

1 reference

4 November 2017

1 reference

4 November 2017

volume

187

1 reference

4 November 2017

issue

3

1 reference

4 November 2017

page(s)

312-320

1 reference

https://scigraph.springernature.com/pub.10.1007/s00213-006-0428-x

4 November 2017

exact match

0 references

cites work

Positive and negative schizophrenic symptoms, attention, and information processing

1 reference

https://api.crossref.org/works/10.1007%2FS00213-006-0428-X

Further evidence for dementia of the prefrontal type in schizophrenia? A controlled study of teaching the Wisconsin Card Sorting Test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-006-0428-X

What are the functional consequences of neurocognitive deficits in schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-006-0428-X

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-006-0428-X

Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-006-0428-X

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-006-0428-X

Risperidone versus haloperidol on secondary memory: can newer medications aid learning?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-006-0428-X

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-006-0428-X

Information processing and attentional functioning in the developmental course of schizophrenic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-006-0428-X

Neuropsychological function in schizophrenia. Selective impairment in memory and learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-006-0428-X

Identification of separable cognitive factors in schizophrenia

21 January 2018

1 reference

12 December 2020

Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry

1 reference

12 December 2020

The Continuous Performance Test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families

1 reference

12 December 2020

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

1 reference

12 December 2020

Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study

1 reference

12 December 2020

A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study

1 reference

12 December 2020

7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.

1 reference

12 December 2020

Effects of clozapine on cognitive function in schizophrenia

1 reference

12 December 2020

Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine.

1 reference

12 December 2020

Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine

1 reference

12 December 2020

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

1 reference

12 December 2020

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

1 reference

12 December 2020

Directional statistical decisions

1 reference

12 December 2020

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

1 reference

12 December 2020

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors

1 reference

12 December 2020

Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS.

1 reference

12 December 2020

Cognitive deficits as treatment targets in schizophrenia

1 reference

12 December 2020

Neurocognitive deficit in schizophrenia: a quantitative review of the evidence.

1 reference

12 December 2020

A Canadian multicenter trial assessing memory and executive functions in patients with schizophrenia spectrum disorders treated with olanzapine

1 reference

12 December 2020

The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients.

1 reference

12 December 2020

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

12 December 2020

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

1 reference

12 December 2020

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

1 reference

12 December 2020

A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.

1 reference

12 December 2020

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

1 reference

12 December 2020

Memory impairment in schizophrenia: a meta-analysis.

1 reference

12 December 2020

10.1007/S00213-006-0428-X

Identifiers

DOI

1 reference

Dimensions Publication ID

4 November 2017

1039897937

0 references

1 reference